Exclusive insights into 928 companies’ emissions data, breakthrough sustainability initiatives, and actionable strategies for net-zero transformation.
Industry at a Tipping Point
Our 2024 analysis reveals the biotech and pharma industry reaching a critical transformation milestone. For the first time, 31% of companies have set medium-term targets aligned with a 1.5°C pathway—up dramatically from just 10 companies last year.
Key Highlights:
- Total sector emissions: 397 million tCO₂-e in 2023
- Scope 3 emissions 5.4x greater than Scope 1 and 2 combined
- 56% of sector revenue committed to UN Race to Zero
- Breakthrough supply chain initiatives showing measurable impact
Download the full report to discover actionable strategies, regional comparisons, and temperature alignment assessments for 638 public and 290 private companies.
Explore our comprehensive archive of industry carbon analysis and sustainability research spanning multiple years of data and insights.
Analyzed 226 public and 147 private companies. Introduced collective supply chain initiatives: Energize, Activate, and Converge programs driving change.
First comprehensive Scope 3 analysis across the value chain. Tracked industry progress since 2015 with 231 public and 151 private companies analyzed.
Groundbreaking first study revealing biotech/pharma emissions exceed forestry and semiconductor industries. Only 4% of companies aligned with 1.5°C goals.